Exeltis - Business Information

Q: What industry does Exeltis belong to?

Exeltis is in the industry of: Pharmaceuticals , Healthcare

Q: What is Exeltis competition?

Exeltis top competitors include: H Lundbeck A/S , Eisai Co. Ltd , Eversana , WebMD Health Corp

Manufacturing · New Jersey, United States · 4,000 Employees

Exeltis is a fast-growing division of Madrid-based Insud Pharma, an integrated health sciences group. It has developed a leading position in the women's health sector, where it continues to discover, develop, produce and seek new medicines and medical devices to improve the health and wellbeing of women around the world. Exeltis strives to provide care for women throughout their lives. Exeltis offers a broad portfolio of products to respond to patients' needs in Women's Health including contraception, pregnancy, birth, and menopause and has expanded its research in recent years to Central Nervous System (CNS), ophthalmology and endocrinology.Read More

View Company Info for Free

Who is Exeltis

Headquarters

180 Park Ave Ste 101, Florham Park, New Jersey, 07932, United States

Phone Number

(973) 324-0200

Website

www.exeltisusa.com

Revenue

$763.4M

Industry

Pharmaceuticals

Healthcare

Is this data correct?

View contact profiles from Exeltis

Popular Searchesexeltis usa IncExeltisExeltis USAExeltis Usa Dermatology LLCExeltis Usa Dermatology IncSIC Code 28,283NAICS Code 45,456Show More

Top Competitors of Exeltis

H Lundbeck A/S
5,353
$2.3B
1
Eisai Co. Ltd
11,322
$5.3B
2
Eversana
7,000
$1.5B
3
WebMD Health Corp
2,000
$293.6M
4
Astellas Pharma Inc
14,522
$9.6B
5
Sunovion Pharmaceuticals Inc
840
$283.6M
6

Exeltis Org Chart

View Exeltis org chart to access information on key employees and get valuable insights about Exeltis organizational structure. The organizational chart highlights the reporting lines within the company, starting with the top decision makers: Satish Joshi, Chief Financial Officer, and Cuneyd Mucasiroglu, Chief Financial Officer.

Phone

Satish Joshi

Chief Financial Officer

Phone

Cuneyd Mucasiroglu

Chief Financial Officer

Phone

View Email Formats for Exeltis

Top Companies in United States

View leading companies in United States by different categories: revenue, number of employees and funding amount. Top companies in United States by revenue is Walmart, by number of employees is Tip Top Poultry and by funding amount is American Airlines. See full lists for all leading companies and additional company information such as contact details, org chart, industry, employees and more.

Exeltis News & Media

Luye Pharma Grants Exeltis Exclusive Commercialization Rights to Its Innovative Alzheimer's Disease Treatment Rivastigmine Multi-Day Transdermal Patch in Mexico and Poland
BASEL, Switzerland, March 31, 2022 /PRNewswire/ -- Luye Pharma Group (Luye Pharma) today announced that its subsidiary Luye Pharma Switzerland AG has entered into agreements with Exeltis Pharma México, S.A. de C.V and Exeltis Pharmaceuticals Holding, S.L (Exeltis), under which the company...
Mar 31, 2022
www.prnewswire.co.uk
Lupin Signs Promotional Agreement with Exeltis on SOLOSEC® (secnidazole) expanding access for Adult Women Suffering with Bacterial Vaginosis and Adults with Trichomoniasis
BALTIMORE, Jan. 27, 2022 /PRNewswire/ -- Lupin Pharmaceuticals Inc., (Lupin), and Exeltis USA Inc. announced a promotional agreement for Exeltis to promote SOLOSEC® along with Exeltis' existing line of Women's Health products, further enhancing value to OBGYNs and their patients. SOLOSEC®...
Jan 27, 2022
www.prnewswire.com
IntelGenx Announces Market Launch of RIZAPORT® in Spain
SAINT LAURENT, Quebec, Sept. 07, 2021 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX V:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that Exeltis Healthcare S.L. (“Exeltis”), its commercialization partner in the European Union (“EU”) for RIZAPORT®, a unique for the treatment of acute migraines, has launched the product in Spain.
Sep 7, 2021
www.globenewswire.com
Aptorum Group Enters into an Agreement with Exeltis to Develop Aptorum’s Novel Preclinical Candidate Targeting Woman’s Gynecological Conditions
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, has entered into an agreement with Exeltis (“Exeltis”) (a division of the global pharmaceutical group Insud Pharma) to develop, manufacture and commercialize a novel preclinical candidate from Aptorum in the following territories: the European Union and Latin America (with an option t
May 6, 2021
www.businesswire.com
IntelGenx and Exeltis Healthcare S.L. Expand RIZAPORT® Commercialization Agreement to Include the European Union
- Agreement Adds 26 Countries to Commercial Territory, with Initial Sales Expected in Early 2021-
Aug 27, 2020
www.globenewswire.com